Eli Lilly

Showing 15 posts of 203 posts found.


NICE recommends Lilly’s Emgality for chronic and episodic migraine

November 18, 2020
Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …


US reserves 300,000 doses of Lilly’s COVID-19 treatment in $375 million deal

October 28, 2020
Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Eli Lilly, US, pharma

The US Government has signed a $375 million deal with Eli Lilly to buy 300,000 700mg doses of bamlanivimab, its …


Eli Lilly refutes FDA quality concerns at New Jersey facility producing COVID-19 drug

October 21, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, FDA, pharma

Eli Lilly has rebutted reports of FDA quality assurance concerns at its manufacturing facility in Branchburg, New Jersey, where it …


Eli Lilly COVID-19 antibody therapy trial paused over safety concerns

October 14, 2020
Research and Development COVID, Eli Lilly, coronavirus

Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns.  …


Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations

October 8, 2020
Manufacturing and Production Eli Lilly, FDA

Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.


Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data

September 15, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir

Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …


Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

July 30, 2020
Research and Development Boehringer, Eli Lilly, jardiance, pharma

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …


Eli Lilly teams up with Chi-Med for Chinese sales of Elunate capsules

July 28, 2020
Manufacturing and Production, Sales and Marketing Chi-Med, China, Eli Lilly

Eli Lilly Shanghai, an affiliate of the wider company, has enlisted the help of biopharma firm Hutchinson China MediTech, or …


Eli Lilly asks for a $24 million tax break for diabetes care facility expansion in Indianapolis

July 24, 2020
Medical Communications Eli Lilly, Humalog, diabetes, insulin

Insulin manufacturer Eli Lilly has requested a $24 million tax break over the next 10 years as an investment into …


Eli Lilly will limit insulin costs to $35 per month for patients in the US due to COVID-19

April 8, 2020
Research and Development Eli Lilly, diabetes, insulin

Eli Lilly announced that it will limit out of pocket costs for insulin to $35 per month to offset the …


Lilly partners with Sitryx in $880m immunometabolism drug development deal

April 1, 2020
Research and Development Eli Lilly, Sitryx, partnership, pharma

Eli Lilly and UK firm Sitryx have partnered up in a new drug development and commercialisation deal that could potentially …

Coronavirus forcing Eli Lilly employees to work from home

March 9, 2020
Sales and Marketing Chinese Coroanvirus, Eli Lilly, Eli Lilly Coronavirus, Wuhan Coronavirus, coronavirus

Eli Lilly is asking some of its employees to work from home to stop the spread of coronavirus on its …


FDA advisory committee narrowly backs Eli Lilly’s Cyramza combo for metastatic EGFR+ NSCLC

February 27, 2020
Sales and Marketing Eli Lilly, FDA, cyramza, pharms

Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs …

Latest content